BACKGROUND AND AIM The increased pancreatic enzymes have recently been reported in patients with severe fever with thrombocytopenia syndrome (SFTS). However, its significance has not been elucidated clearly. The aim of this study was to explore the prevalence, clinical characteristics of elevated pancreatic enzymes (amylase and lipase) and its association with AP in patients with SFTS. METHODS Data of demographics, comorbid conditions, clinical symptoms, laboratory parameters and survival time of patients with SFTS were collected. Patients were assigned into the non-AP and AP groups according to the diagnostic criteria of AP. Patients in the non-AP group were divided into the normal (3×ULN) groups according to the serum amylase and lipase levels, and then their clinical data were compared. RESULTS A total of 284 patients diagnosed with SFTS were retrospectively enrolled, including 248 patients in the non-AP group and 36 patients in the AP group. Patients in the non-AP group were composed of 48, 116 and 84 patients in the normal, EPE and HPE groups, respectively. Compared with patients in the normal and EPE groups, patients in the HPE group had higher serum levels of laboratory parameters referring to liver, kidney, heart and coagulation system injury, as well as higher viral load. The cumulative survival rate of patients in the HPE group was significantly lower than that of patients in the normal group. In addition, patients in the AP group also had higher serum levels of laboratory variables reflecting liver, heart, coagulation dysfunction and viral load than patients in the HPE group. The cumulative survival rate of patients in the AP group was significantly lower than that of patients in the HPE group. CONCLUSION The increased pancreatic enzymes are very common in patients with SFTS, but they are not always associated with AP. Though AP accounts for the majority of deaths for patients with elevated pancreatic enzymes, patients with pancreatic enzymes >3×ULN except for AP also have a high in-hospital mortality rate.

中文翻译：

---

严重发热伴血小板减少综合征患者胰酶升高的患病率和临床特征。

背景和目的 最近报道严重发热伴血小板减少综合征（SFTS）患者的胰酶升高。然而，其意义尚未明确阐明。本研究的目的是探讨 SFTS 患者胰酶（淀粉酶和脂肪酶）升高的患病率、临床特征及其与 AP 的关系。方法 收集 SFTS 患者的人口统计学、合并症、临床症状、实验室参数和生存时间数据。根据AP诊断标准将患者分为非AP组和AP组。非AP组患者分为正常组（3×ULN）根据血清淀粉酶和脂肪酶水平进行分组，然后比较其临床数据。结果 回顾性纳入284例确诊为SFTS的患者，其中非AP组248例，AP组36例。非AP组患者中，正常组、EPE组和HPE组分别有48例、116例和84例患者。与正常组和EPE组患者相比，HPE组患者的血清肝、肾、心脏和凝血系统损伤等实验室指标水平较高，病毒载量也较高。HPE组患者的累积生存率显着低于正常组患者。此外，AP组患者的反映肝脏、心脏、凝血功能障碍和病毒载量的实验室变量血清水平也高于HPE组患者。AP组患者的累积生存率显着低于HPE组患者。结论 SFTS 患者胰酶升高很常见，但并不总是与 AP 相关。尽管AP占胰酶升高患者死亡的大部分，但除AP外，胰酶>3×ULN的患者也具有较高的院内死亡率。